SAB Biotherapeutics (SABS) Cash from Investing Activities (2021 - 2026)

SAB Biotherapeutics (SABS) has 6 years of Cash from Investing Activities data on file, last reported at -$65.6 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 1505.4% year-over-year to -$65.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$192.0 million (down 897.84% YoY) and the FY2025 annual result came in at -$121.7 million, down 917.42% from the prior year.
• Cash from Investing Activities eased to -$65.6 million in Q1 2026, from -$1.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $11.2 million in Q2 2024 to a low of -$129.9 million in Q3 2025.
• A 5-year average of -$11.9 million and a median of -$78504.0 in 2022 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 49556.96% in 2024, down 147126.32% in 2024.
• Tracing SABS's Cash from Investing Activities over 5 years: stood at -$117754.0 in 2022, then surged by 42.37% to -$67864.0 in 2023, then jumped by 13849.21% to $9.3 million in 2024, then sank by 118.29% to -$1.7 million in 2025, then tumbled by 3747.7% to -$65.6 million in 2026.
• The last three Cash from Investing Activities figures came in at -$65.6 million (Q1 2026), -$1.7 million (Q4 2025), and -$129.9 million (Q3 2025), per Business Quant data.